Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver G Ottmann

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Plos One|November 19, 2013
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemiaSusanne Badura, Tamara Tesanovic, Heike Pfeifer, et al.
Blood|February 28, 2002
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutationWolf-K Hofmann, Letetia C Jones, Nathan A Lemp, et al.
Blood|May 24, 2003
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylateJunya Kuroda, Shinya Kimura, Hidekazu Segawa, et al.
Blood|October 24, 2002
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)Urban J Scheuring, Heike Pfeifer, Barbara Wassmann, et al.
Cancer Science|February 18, 2004
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acidJunya Kuroda, Shinya Kimura, Hidekazu Segawa, et al.
Cytotherapy|November 27, 2016
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphomaSarah Oelsner, Miriam E Friede, Congcong Zhang, et al.
British Journal of Haematology|August 16, 2005
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growthHidekazu Segawa, Shinya Kimura, Junya Kuroda, et al.
Clinical Epigenetics|June 19, 2012
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidAndrea Kuendgen, Gesine Bug, Oliver G Ottmann, et al.
International Journal of Oncology|January 5, 2007
Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiationSteffen Koschmieder, Shuchi Agrawal, Hanna S Radomska, et al.
Haematologica|August 1, 2020
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstatElisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Plos One|November 19, 2013
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemiaSusanne Badura, Tamara Tesanovic, Heike Pfeifer, et al.
Blood|February 28, 2002
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutationWolf-K Hofmann, Letetia C Jones, Nathan A Lemp, et al.
Blood|May 24, 2003
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylateJunya Kuroda, Shinya Kimura, Hidekazu Segawa, et al.
Blood|October 24, 2002
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)Urban J Scheuring, Heike Pfeifer, Barbara Wassmann, et al.
Cancer Science|February 18, 2004
p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acidJunya Kuroda, Shinya Kimura, Hidekazu Segawa, et al.
Cytotherapy|November 27, 2016
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphomaSarah Oelsner, Miriam E Friede, Congcong Zhang, et al.
British Journal of Haematology|August 16, 2005
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growthHidekazu Segawa, Shinya Kimura, Junya Kuroda, et al.
Clinical Epigenetics|June 19, 2012
Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acidAndrea Kuendgen, Gesine Bug, Oliver G Ottmann, et al.
International Journal of Oncology|January 5, 2007
Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiationSteffen Koschmieder, Shuchi Agrawal, Hanna S Radomska, et al.
Haematologica|August 1, 2020
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstatElisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, et al.
Pageof 11